[Analysis of voriconazole serum concentrations and safety profile in pediatric oncology patients].
BACKGROUND
Voriconazole (VCZ) serum drug levels (SDL) vary widely and are associated with increased mortality when they are below the therapeutic range for invasive aspergillosis (IA).


OBJECTIVE
To describe VCZ SDL in oncology pediatric patients in order to reach adequate concentrations for prophylaxis (≥ 0.5 mg/L) and treatment (≥ 1.0 y 2.0 mg/L) for IA and their relationship with toxicity.


METHODS
Retrospective analysis of VCZ SDL and toxicities recorded in oncology pediatric patients between February 2013 and November 2014. The daily dosage and SDLs were analyzed according to administration route: intravenous (IV) and oral (PO), type of therapy (prophylaxis and treatment) and patient age (< 12 y ≥ 12 years old).


RESULTS
112 through levels from 26 patients were analyzed and the average age was 9.3 years-old. The SDL obtained from the IV route were 43.7%. There were more SDL ≥ 0.5 mg/L and ≥ 1.0 mg/L with the IV route than the PO route (p < 0.05). Patients younger than 12-years-old received a higher dosage than those ≥ 12 years old (median 18.6 and 9.2 mg/kg/d, respectively, p < 0.05). To reach SDL ≥ 0,5 mg/L with the PO route, a dosage of 200 mg every 12 hours showed the best results for all patients (80-100% SDL ≥ 0.5 mg/L). With an IV dosage between 14 and 20 mg/kg/day in patients > 12-years-old, 80% of the SDL were ≥ 1 mg/L and ≥ 2 mg/L. In patients younger than 12-year-old, dosages between 8-30 mg/ kg/day showed similar results (50-63% of SDL ≥ 1 mg/L and 36-40% of SDL ≥ 2 mg/L). Eight patients (30.8%) presented an adverse drug reaction and no relationship with the SDL was found. Conclusión: A VCZ standard dosage of 200 mg every 12 hours PO showed the best results for IA prophylaxis in all patients. Patients younger than 12-years-old would require higher dosages than the doses used in this study to attain adequate SDL for IA treatment. No relation with SDL and adverse reactions was found.
Felipe
F
Silva
Daniel
D
Navea
Carolina
C
Saias
Juan P
JP
Torres
Paula
P
Catalán
Jorge
J
Morales
D000284:Administration, Oral; D000293:Adolescent; D000367:Age Factors; D000935:Antifungal Agents / Q000008:administration & dosage* / Q000097:blood*; D001228:Aspergillosis / Q000188:drug therapy; D002648:Child; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D016903:Drug Monitoring; D005260:Female; D006801:Humans; D007121:Immunocompetence / Q000187:drug effects; D007275:Injections, Intravenous; D008297:Male; D009369:Neoplasms / Q000276:immunology* / Q000382:microbiology; D060735:Pharmacovigilance; D012016:Reference Values; D012189:Retrospective Studies; D018709:Statistics, Nonparametric; D016896:Treatment Outcome; D065819:Voriconazole / Q000008:administration & dosage* / Q000097:blood*
D000935:Antifungal Agents; D065819:Voriconazole